At what enterprise value was CEVA SANTE ANIMALE acquired in 2014?

During the acquisition of CEVA SANTE ANIMALE by INSTITUT MERIEUX / SAGARD / SOFIPROTEOL in 2014, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR.

What was the EV/EBITDA of CEVA SANTE ANIMALE when it was acquired by INSTITUT MERIEUX / SAGARD / SOFIPROTEOL?

The estimated EV/EBITDA multiple for CEVA SANTE ANIMALE is in the range of 10x - 18x.

What was the revenue of CEVA SANTE ANIMALE at the time of the deal?

The revenue of CEVA SANTE ANIMALE at the time of the deal is estimated to be in the range of 450M - 900M EUR.

What was the EBITDA of CEVA SANTE ANIMALE during the acquisition?

CEVA SANTE ANIMALE's EBITDA is estimated to be in the range of 100M - 200M EUR.

How is the data for the CEVA SANTE ANIMALE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CEVA SANTE ANIMALE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/ceva-sante-animale-sassocie-a-merieux-developpement-107627

← DATABASE

Home Database Healthcare & PharmaCEVA SANTE ANIMALE

09/2014

CEVA SANTE ANIMALE acquired by INSTITUT MERIEUX, SAGARD & SOFIPROTEOL

FRANCE Life Sciences / Animal Health EV 1b - 4b EUR

Context

Ceva announced the entry of Merieux Developpement (investment arm of Institut Merieux) into its capital, finalizing the syndicate for its fourth LBO. Merieux joins Asian investors Temasek and CDH Investments, as well as French funds Sagard, Euromezzanine, and Sofiproteol. The strategic rationale is to leverage Institut Merieux's scientific network to fight emerging diseases and antibiotic resistance, and to accelerate Ceva's expansion in Asia (China).

CEVA SANTE ANIMALE, which reported an EBITDA margin of in 2013, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Ceva is the 5th largest animal health company in the world. Headquartered in Libourne, it employs 7,000 people in 47 countries. The group balances its activity between preventive medicine (vaccines) and pharmaceutical products for poultry, swine, ruminants, and pets (30% of sales). It invests ~10% of revenue in R&D.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2013

2012

Other operations with CEVA SANTE ANIMALE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
02/2020	TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO	CEVA SANTE ANIMALE	FRANCE	Animal Health

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CEVA SANTE ANIMALE by INSTITUT MERIEUX / SAGARD / SOFIPROTEOL are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: ceva sante animale

Acquirer: sofiproteol / sagard / institut merieux